LON:FAB Fusion Antibodies (FAB) Share Price, News & Analysis GBX 4 -0.25 (-5.88%) As of 03:39 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsInsider TradesNews and Trends About Fusion Antibodies Stock (LON:FAB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Fusion Antibodies alerts:Sign Up Key Stats Today's Range 4▼ 4.2550-Day Range 4▼ 12.1252-Week Range 3.50▼ 20Volume104 shsAverage Volume476,057 shsMarket Capitalization£5.01 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue. The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation. Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process. The global monoclonal antibody therapeutics market was valued at $186 billion in 2021 and is forecast to surpass $445 billion in 2028, an increase at a CAGR of 13.2 per cent. for the period 2022 to 2028. Approximately 150 monoclonal antibody therapies are approved and marketed globally as of June 2022 with the top four antibody drugs each having sales of more than $3 bn in 2021. Read More Receive FAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fusion Antibodies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FAB Stock News HeadlinesFusion Antibodies Plc (FAB) AI Stock AnalysisNovember 12, 2026 | tipranks.comFusion Antibodies Wins Complex Antibody Development Contract with Global Pharma ClientOctober 22, 2026 | tipranks.comUnder 3 cents a nightBill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it. | Profits Run (Ad)Fusion's H1 Revenue Drop In FY27 Addressed At Annual General Meeting; Shares Plunge By Over 35%October 15, 2026 | rttnews.comFusion Antibodies shares fall 41% as difficult market conditions hit performanceOctober 15, 2026 | uk.finance.yahoo.comLaunch of new customer-focused websiteOctober 6, 2026 | markets.ft.comFusion Antibodies launches revamped customer-focused website to showcase antibody servicesOctober 5, 2026 | tipranks.comPosting of Annual Report & Notice of AGMSeptember 22, 2026 | markets.ft.comSee More Headlines FAB Stock Analysis - Frequently Asked Questions How have FAB shares performed this year? Fusion Antibodies' stock was trading at GBX 13.76 on January 1st, 2026. Since then, FAB shares have decreased by 70.9% and is now trading at GBX 4. How were Fusion Antibodies' earnings last quarter? Fusion Antibodies plc (LON:FAB) posted its earnings results on Monday, September, 14th. The company reported GBX (1.20) EPS for the quarter. Fusion Antibodies had a negative net margin of 54.45% and a negative trailing twelve-month return on equity of 97.87%. How do I buy shares of Fusion Antibodies? Shares of FAB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Company Calendar Last Earnings9/14/2026Today11/19/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolLON:FAB CIKN/A Webfusionantibodies.com Phone+44-28-90432800FaxN/AEmployees24Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (1) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£4.10 million Net Margins-54.45% Pretax MarginN/A Return on Equity-97.87% Return on Assets-63.78% Debt Debt-to-Equity Ratio20.41 Current Ratio2.82 Quick Ratio2.36 Sales & Book Value Annual Sales£2.11 million Price / Sales2.37 Cash FlowGBX 0.44 per share Price / Cash Flow9.02 Book ValueGBX 3.51 per share Price / Book1.14Miscellaneous Outstanding Shares125,157,000Free FloatN/AMarket Cap£5.01 million OptionableNot Optionable Beta1.24 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (LON:FAB) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fusion Antibodies plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Fusion Antibodies With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.